Fairvalue-Calculator Fairvalue-Calculator
EN DE

ADBiotech Co (179530) Fair Value & Analysis

Healthcare · KR · Market cap 46.1B KRW

Price1,919 KRW
Fair Value3,460 KRW
Upside+80.3%
Quality90/100
Evidence: Low Range 2,595 KRW – 4,325 KRW

Fair value as of: Jun 24, 2026

✦ Screen 34,000+ stocks by fair value & quality — free Start the tool →

Analysis

ADBiotech Co (179530) currently trades at 1,919 KRW, while our model-based Fair Value estimate is 3,460 KRW — implying the stock looks roughly 80.3% undervalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

ADBiotech Co., Ltd. develops and sells antibodies for livestock, fisheries, and humans in South Korea and internationally. The company offers antibiotic, disinfectant, helminthic, over the counter drugs, supplementary feed, and metabolic drugs. It also offers health functional and processed foods. ADBiotech Co., Ltd. was founded in 2000 and is based in Chuncheon-si, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is ADBiotech Co (179530) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 3,460 KRW versus a price of 1,919 KRW — about +80% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 179530?
Our 21-model fair value for ADBiotech Co is 3,460 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 1,919 KRW.
What is the quality score of 179530?
ADBiotech Co has a Quality Score of 90/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.